CLINICAL TRIALS PROFILE FOR DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00528879 ↗ | A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone | Completed | Bristol-Myers Squibb | Phase 3 | 2007-09-01 | The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone. The safety of this treatment will also be studied. |
| NCT00528879 ↗ | A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone | Completed | AstraZeneca | Phase 3 | 2007-09-01 | The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone. The safety of this treatment will also be studied. |
| NCT00546741 ↗ | Drug Interaction With Metformin | Completed | Bristol-Myers Squibb | Phase 1 | 2007-11-01 | The purpose of the study is to determine the effect of metformin on dapagliflozin exposure and the effect of dapagliflozin on metformin exposure in healthy volunteers. Additionally, the safety and tolerability of dapagliflozin will be assessed in the presence and absence of metformin in healthy volunteers |
| NCT00546741 ↗ | Drug Interaction With Metformin | Completed | AstraZeneca | Phase 1 | 2007-11-01 | The purpose of the study is to determine the effect of metformin on dapagliflozin exposure and the effect of dapagliflozin on metformin exposure in healthy volunteers. Additionally, the safety and tolerability of dapagliflozin will be assessed in the presence and absence of metformin in healthy volunteers |
| NCT00643851 ↗ | An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets | Completed | Astra Zeneca, Bristol-Myers Squibb | Phase 3 | 2008-06-01 | The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any pharmacological treatment for diabetes, when compared to initial treatment with monotherapy dapagliflozin or metformin XR. The safety of this treatment will also be studied |
| NCT00643851 ↗ | An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets | Completed | AstraZeneca | Phase 3 | 2008-06-01 | The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any pharmacological treatment for diabetes, when compared to initial treatment with monotherapy dapagliflozin or metformin XR. The safety of this treatment will also be studied |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Condition Name
Clinical Trial Locations for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Sponsor Name
